We’re pleased to share that our experts – Elisabeth (Els) Coart, Everardo Saad and Marc Buyse – were co-authors of the article Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors published in European Journal of Cancer.

The article gives an insight into the recent changes in the adjuvant treatment of melanoma that have raised interest in confirming relapse-free survival (RFS) as a surrogate for overall survival (OS).

The article can be accessed for 50 days free of charge. Read more about the article and get the link on our website: http://ow.ly/11TG50AWUVF

See all Member News